Theme: Malaria, TB and Neglected Tropical Diseases: Progress in Drug Discovery and Development

Topics include:

  • Malaria Drug Discovery
  • Tuberculosis Drug Discovery
  • Neglected Tropical
  • Diseases Drug Discovery
  • Drug Resistance
  • Pharmacogenomics
  • Drug Safety

Programme outline:

Tue 15 November
15h00 – 17h00


17h00 – 17h15 Kelly Chibale (Director, H3D, SA) Opening welcome and CHAIR
17h15 – 18h00 Ken Duncan (Bill & Melinda Gates Foundation, USA) Partnerships and progress in discovery of new drugs for malaria, tuberculosis and neglected tropical diseases
18h00 – 18h30 Paul Herrling (Novartis Institute Tropical Diseases, Switzerland) Addressing Unmet Medical Need of the Developing World Through Collaborative Innovation
18h30 – 19h00 Nick Cammack (GlaxoSmithKline, Spain) Learnings from open drug discovery for diseases of the developing world
Wed 16 November
THEME Global Health Perspectives in the Pharmaceutical Industry (CHAIR: Leslie Street)
08h30 – 09h00 Thomas Spangenberg (Merck, Switzerland) The Merck Global Health Institute: Integrated Health Solutions for Developing Economies
09h00 – 09h30 Fabian Gusovsky (Eisai Inc, USA) Eisai’s portfolio in Global Health
09h30 – 10h00 Joe Camardo (Celgene Global Health, USA) Celgene Global Health:  Expertise, Commitment, and Partnership for Neglected Diseases
10h00 – 10h30


THEME Global Health Perspectives in Product Development Partnerships (CHAIR: Gregory Basarab)
10h30 – 11h00 Graeme Bilbe (Drugs for Neglected Diseases initiative, Switzerland) Innovating in New Drugs for Kinetoplastid Diseases.
11h00 – 11h30 Nader Fotouhi (TB Alliance, USA) Searching for a (short) universal regimen for tuberculosis treatment
11h30 – 12h00 Tim Wells (Medicines for Malaria Venture, Switzerland) Open Source Collaborations to Catalyse Discovery of New Medicines
12h00 – 12h30 Michael Witty (Global Alliance for Livestock Veterinary Medicines, UK) GALVmed African Trypanosomosis Drug Discovery program
12h30 – 13h00 Frank von Delft (Oxford Univ, UK) Expanding Targeting Opportunities with XChem Fragment-Based Screening
13h00 – 14h00


THEME Target and Phenotypic screening (CHAIRS: Edward Sturrock / Tim Egan)
14h00 – 14h30 Kevin Saliba (The Australian National University, AU) Targeting coenzyme A biosynthesis in the human malaria parasite Plasmodium falciparum
14h30 – 15h00 Mathew Bogyo (Stanford Univ, USA) The Plasmodium proteasome as an anti-malarial drug target
15h00 – 15h15 Joanna Evans (Molecular Mycobacteriology Res Unit, Univ of Cape Town, SA) Validation of CoaBC as a bactericidal target in the coenzyme A pathway of Mycobacterium tuberculosis
15h15 – 15h30 Vinayak Singh (Molecular Mycobacteriology Res Unit, Univ of Cape Town, SA The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis
15h30 – 15h45 Dirk Lamprecht (KRITH, SA) Turning the respiratory flexibility of Mycobacterium tuberculosis against itself
15h45 – 16h30

POSTERS 1 – 26

16h30 – 17h00 Tanya Parish (Infectious Disease Research Institute, USA) Alternative phenotypic approaches for Mycobacterium tuberculosis screening
17h00 – 17h30 Lyn-Marie Birkholtz (Univ of Pretoria, SA) Towards transmission-blocking antimalarials: what will be the outcome of high-content biological screens for malaria elimination?
Thur 17 November
THEME Identifying and Optimising Leads (CHAIRS: Joe Eyermann / Alissa Myrick)
08h30 – 09h00 Pascal Mäser (Swiss Tropical and Public Health Institute, Switzerland) New drugs to support the elimination of human African trypanosomiasis
09h00 – 09h30 Ian Gilbert (Drug Discovery Unit, Univ of Dundee, UK) Drug Discovery for Neglected Diseases
09h30 – 10h00 Rui Moreira (Univ of Lisbon, Portugal) Identification and optimization of a novel chemotype with antileishmanial and dual-stage antimalarial activities
10h00 – 10h30


10h30 – 11h00 Jonathan Vennerstrom (Univ of Nebraska, USA) Antimalarial ozonides
11h00 – 11h30 Michael Pollastri (Northeastern Univ, USA) Efforts in kinase inhibitor lead repurposing for neglected tropical diseases
11h30 – 12h00 Richard Lee (St Jude’s Hospital, USA) Advancing Spectinomycin Analogs for New Therapeutics
12h00 – 12h15 Marianne de Villiers (Univ of Stellenbosch SA) Pantetheinase-Resistant Pantothenamides with Potent, On-Target, and Selective Antiplasmodial Activity
12h15 – 12h30 Phanankosi Moyo (Univ of Pretoria, SA) Bioassay guided isolation and characterisation of antigametocyte compounds from Artemisia afra
12h30 – 12h45 Dina Coertzen (Univ of Pretoria, SA) Potent pan-reactive 10-alkylaminoartemisinins for development of triple drug antimalarial combinations
12h45 – 13h00 Bianca Verlinden (Univ of Pretoria, SA) Multitarget antimalarial polyamine analogues: resisting resistance
13h00 – 14h00


THEME Pharmacokinetics and other drug discovery Platform technologies (CHAIRS: Nina Lawrence / Dale Taylor)
14h00 – 14h30 Jennifer Keiser (Swiss Tropical Public Health Institute, Switzerland) Schistosomiasis and praziquantel: from dose-finding to pharmacokinetic studies
14h30 – 15h00 Dennis Smith (Consultant, UK) Physicochemical and pharmacokinetic correlations for anti-TB drugs
15h00 – 16h30

POSTERS 27- 52

Fri 18 November
THEME Transitioning Drug Discovery Assets Towards Preclinical and Clinical Development (CHAIRS: Rudolf Mueller /Sandeep Ghorpade)
09h30 – 10h00 Rod Dawson (Lung Inst, Univ Cape Town) TB Clinical Trial Development- The Bedaquiline Experience
10h00 – 10h30 Paul van Helden (Univ of Stellenbosch, SA) Drug Susceptibility testing: yesterday, today and tomorrow in the context of heteroresistance
10h30 – 11h00


11h00 – 11h30 Tanya Paquet (H3D, Univ Cape Town, SA) Advancing aminopyrazines as antimalarial agents
11h30 – 11h45 Clif Barry (Nat Inst of Allergy & Infectious Diseases, Nat. Inst of Health, USA) Radiologic and immunologic biomarkers to enhance early bactericidal activity measurements of sterilizing drug activity in tuberculosis (NexGen EBA)
11h45 – 12h30 Clif Barry (National Inst of Allergy and Infectious Diseases, USA) Is there a scientific pathway to treatment-shortening for tuberculosis?
12h30 – 12h45 Kelly Chibale (Director, H3D, SA) Closing remarks